Candel Therapeutics Inc. Common Stock (CADL)

About CADL

Candel Therapeutics, Inc., a clinical stage biopharmaceutical company, develops immunotherapies for cancer patients. It develops CAN-2409, which is in Phase 2a clinical trials for the treatment of prostate cancer; and Phase 2a clinical trials for the treatment of non-small cell lung cancer (NSCLC). The company is also developing CAN-3110, which is in Phase Ib clinical trials for the treatment of recurrent high-grade…

Sector

Health Care

Industry

Biotechnology: Biological Products (No Diagnostic Substances)

Employees

55

Website

www.candeltx.com

Fundamentals

1-day range

$11.04$11.95

Market cap

$775.20M

P/E (trailing)

—

P/E (forward)

-18.75

EPS (trailing)

$-1.47

Dividend yield

—

Beta

-0.50

Avg. volume

1.69M

Forecasts

8 analyst ratings

Candel Therapeutics Inc. Common Stock Competitors

Chosen by industry and closest market cap.

• CADL

  Candel Therapeutics Inc. Common Stock

  $13.07

  ▼ 4.95%
  Market cap $775.20MP/E —
  $4.35$11.95
• SLDB

  Solid Biosciences Inc. Common Stock

  $9.78

  ▼ 3.46%
  Market cap $857.50MP/E —
  $3.79$11.45
• ALLO

  Allogene Therapeutics Inc. Common Stock

  $2.01

  ▼ 3.83%
  Market cap $679.95MP/E —
  $1.04$4.46
• AGMB

  AgomAb Therapeutics NV American Depositary Shares

  $13.17

  ▼ 4.84%
  Market cap $664.85MP/E —
  $8.75$17.82
• SANA

  Sana Biotechnology Inc. Common Stock

  $3.93

  ▼ 3.91%
  Market cap $948.97MP/E —
  $2.61$6.55
• RGNX

  REGENXBIO Inc. Common Stock

  $9.66

  ▲ 3.09%
  Market cap $583.15MP/E —
  $5.46$16.19
• TECX

  Tectonic Therapeutic Inc. Common Stock

  $35.69

  ▼ 2.75%
  Market cap $570.23MP/E —
  $14.39$39.53

P/E shows — for peers not currently carrying a live signal of their own.

Latest news

• B of A Securities Maintains Neutral on Candel Therapeutics, Raises Price Target to $12
  Benzinga · 8/14/2026
• HC Wainwright & Co. Reiterates Buy on Candel Therapeutics, Maintains $23 Price Target
  Benzinga · 8/13/2026
• Candel Therapeutics Q2 EPS $(0.52) Misses $(0.23) Estimate
  Benzinga · 8/13/2026
• Candel Therapeutics: Getting Closer, And Building Out More Paths
  SeekingAlpha · 8/7/2026
• Candel Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
  Yahoo · 8/3/2026
• Candel Therapeutics to Present Extended Data from Phase 3 Results of Aglatimagene Besadenovec at ASTRO 2026
  Yahoo · 8/3/2026

• Sims Mark E. · July 6, 2026 · Grant

  285.0K
• Nicoletta Loggia · June 30, 2026 · Grant

  381 @ $8.64
• Paul B. Manning · June 30, 2026 · Grant

  2.2K @ $8.64
• Joseph C. Papa · June 30, 2026 · Grant

  1.3K @ $8.64
• Seshu Tyagarajan · June 29, 2026 · Sale

  7.0K @ $10.02
• Francesca Barone · June 29, 2026 · Sale

  23.4K @ $10.06
• Radhakrishnan Maha · June 23, 2026 · Grant

  32.0K
• Nicoletta Loggia · June 23, 2026 · Grant

  32.0K
• Christopher Martell · June 23, 2026 · Grant

  32.0K
• Gary J. Nabel · June 23, 2026 · Grant

  32.0K
• Nguyen Diem · June 23, 2026 · Grant

  32.0K
• Renee Gaeta · June 23, 2026 · Grant

  32.0K
• Benz Edward J. JR · June 23, 2026 · Grant

  32.0K
• Paul B. Manning · June 23, 2026 · Grant

  32.0K
• Joseph C. Papa · June 23, 2026 · Grant

  32.0K

Institutional Ownership

March 31, 2026

Total shares held

43.13M

Total value held

$211.00M

Institutional holders

110